Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Practice Guideline
. 2013 Jul;11(7):753-60; quiz 761.
doi: 10.6004/jnccn.2013.0098.

Breast cancer, version 3.2013: featured updates to the NCCN guidelines

Richard L Theriault  1 , Robert W Carlson, Craig Allred, Benjamin O Anderson, Harold J Burstein, Stephen B Edge, William B Farrar, Andres Forero, Sharon Hermes Giordano, Lori J Goldstein, William J Gradishar, Daniel F Hayes, Clifford A Hudis, Steven J Isakoff, Britt-Marie E Ljung, David A Mankoff, P Kelly Marcom, Ingrid A Mayer, Beryl McCormick, Lori J Pierce, Elizabeth C Reed, Lee S Schwartzberg, Mary Lou Smith, Hatem Soliman, George Somlo, John H Ward, Antonio C Wolff, Richard Zellars, Dorothy A Shead, Rashmi Kumar; National Comprehensive Cancer Network
Affiliations
Practice Guideline

Breast cancer, version 3.2013: featured updates to the NCCN guidelines

Richard L Theriault et al. J Natl Compr Canc Netw. 2013 Jul.

Abstract

These NCCN Guidelines Insights highlight the important updates specific to the management of HER2-positive metastatic breast cancer in the 2013 version of the NCCN Clinical Practice Guidelines in Oncology for Breast Cancer. These include new first-line and subsequent therapy options for patients with HER2-positive metastatic breast cancer.

PubMed Disclaimer

Figures

None
NCCN Guidelines Insights, Breast Cancer, Version 3.2013.
None
NCCN Guidelines Insights, Breast Cancer, Version 3.2013.
None
NCCN Guidelines Insights, Breast Cancer, Version 3.2013.
None
NCCN Guidelines Insights, Breast Cancer, Version 3.2013.
None
NCCN Guidelines Insights, Breast Cancer, Version 3.2013.
See this image and copyright information in PMC

References

    1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11–30. - PubMed
    1. Wolff AC, Hammond MEH, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007;25:118–145. - PubMed
    1. Dawood S, Broglio K, Buzdar AU, et al. Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. J Clin Oncol. 2010;28:92–98. - PMC - PubMed
    1. Carlson RW, Moench SJ, Hammond ME, et al. HER2 testing in breast cancer: NCCN Task Force report and recommendations. J Natl Compr Canc Netw. 2006;4(Suppl 3):1–22. - PubMed
    1. Paik S, Bryant J, Tan-Chiu E, et al. Real-world performance of HER2 testing—National Surgical Adjuvant Breast and Bowel Project experience. J Natl Cancer Inst. 2002;94:852–854. - PubMed

Publication types

Substances